Compare CMPR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | NRIX |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2005 | 2020 |
| Metric | CMPR | NRIX |
|---|---|---|
| Price | $100.16 | $22.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $86.50 | $30.50 |
| AVG Volume (30 Days) | 260.6K | ★ 2.2M |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $3,403,079,000.00 | $76,987,000.00 |
| Revenue This Year | $10.43 | N/A |
| Revenue Next Year | $5.46 | $48.05 |
| P/E Ratio | $34.77 | ★ N/A |
| Revenue Growth | 3.38 | ★ 99.31 |
| 52 Week Low | $42.08 | $8.20 |
| 52 Week High | $106.13 | $25.09 |
| Indicator | CMPR | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 64.37 |
| Support Level | $62.76 | $14.86 |
| Resistance Level | $105.93 | $24.88 |
| Average True Range (ATR) | 4.34 | 1.42 |
| MACD | 0.74 | 0.16 |
| Stochastic Oscillator | 75.86 | 70.76 |
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.